open access
Vol 27, No 1 (2020)
Editorial
Submitted: 2020-02-24
Accepted: 2020-02-24
Published online: 2020-02-25
Get Citation
To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention
1, 2, 3
Affiliations- Division of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea
- Department of Cardiology, Bristol Heart Institute, Bristol, United Kingdom
- Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea
open access
Vol 27, No 1 (2020)
Editorial
Submitted: 2020-02-24
Accepted: 2020-02-24
Published online: 2020-02-25
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention
Journal
Issue
Article type
Editorial
Pages
1-3
Published online
2020-02-25
Page views
1989
Article views/downloads
1132
DOI
Pubmed
Bibliographic record
Cardiol J 2020;27(1):1-3.
Authors
Yongcheol Kim
Thomas W. Johnson
Young-Hoon Jeong
References (10)- Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019; 21(2): 192–193.
- Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423–2434.
- Cannon C, Bhatt D, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
- Lopes R, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019; 380(16): 1509–1524.
- Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206): 1335–1343.
- Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019; 139(5): 604–616.
- Yasuda S, Kaikita K, Akao M, et al. AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019; 381(12): 1103–1113.
- Huo Y, Jeong YH, Gong Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Science Bulletin. 2019; 64(3): 166–179.
- Franchina AG, Calderone D, D'Arrigo P, et al. Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome. Cardiol J. 2020; 27(1): 8–15.
- Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019; 140(3): 240–261.
